AROAF (Aroa Biosurgery) LT-Debt-to-Total-Asset: 0.04 (As of Mar. 2026)

What is Aroa Biosurgery LT-Debt-to-Total-Asset?

Aroa Biosurgery AROAF +35.24% 39 LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aroa Biosurgery's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.04.

Aroa Biosurgery's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.04). It may suggest that Aroa Biosurgery is progressively becoming less dependent on debt to grow their business.

Aroa Biosurgery (OTCPK:AROAF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aroa Biosurgery LT-Debt-to-Total-Asset Related Terms

Aroa Biosurgery LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery LT-Debt-to-Total-Asset Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.06

0.05

0.04

Aroa Biosurgery Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial								0.06	0.06	0.05	0.05	0.04

39GF Score

Aroa Biosurgery Ltd AROAF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aroa Biosurgery LT-Debt-to-Total-Asset Calculation

Aroa Biosurgery's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	2.865	/	70.599
	=	0.04

Aroa Biosurgery's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	2.865	/	70.599
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Aroa Biosurgery (AROAF) has a LT-Debt-to-Total-Asset of 0.04 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aroa Biosurgery and its competitors.

Is Aroa Biosurgery's LT-Debt-to-Total-Asset too high?

Aroa Biosurgery's current LT-Debt-to-Total-Asset is 0.04. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Aroa Biosurgery's LT-Debt-to-Total-Asset compare to ABT and SYK?

Aroa Biosurgery's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aroa Biosurgery stock overvalued right now?

Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (AROAF) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for AROAF:

LT-Debt-to-Total-Asset: 0.04
GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
GF Score™: 39/100 with 1 warning sign

No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ASX:EMV ASX:SOM ASX:LDX ASX:COV ASX:CMP ASX:HMD ASX:CBL ASX:CSX ASX:EYE ASX:MX1 ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges ARX:Australia

Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website https://www.aroa.com

Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.

39GF Score

Get the complete analysis for AROAF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52

Price

$0.71

GF Value

View AROAF Analysis

See LT-Debt-to-Total-Asset data for all stocks →